ReviewVaccine2022
Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?
Review in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Efficacy, immunogenicity, and safety of BCG revaccination against Mycobacterium tuberculosis: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2026Pooled it
- Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.The Lancet. Infectious diseases · 2024Trial
- The impact of circadian rhythm on Bacillus Calmette-Guérin vaccination effects on SARS-CoV-2 infections.Frontiers in immunology · 2023Trial
- Reframing evidence on the BCG vaccine: What emerging systematic reviews and meta-analyses reveal about efficacy, safety, and heterogeneity.Human vaccines & immunotherapeutics · 2026Article
- Unleashing the power of the BCG vaccine in modulating viral immunity through heterologous protection: A scoping review.Human vaccines & immunotherapeutics · 2025Article
- Dendritic Cell Vaccine Harboring Inactivated Mycobacteria Induces Immune Protection Against Tuberculosis in Murine Models and is Well Tolerated in Humans.Small science · 2025Article
- Intranasal BCG vaccination induces systemic and pulmonary mucosal immune responses against tuberculosis in a goat model.Frontiers in immunology · 2025Article
- Challenges in developing new tuberculosis vaccines.Memorias do Instituto Oswaldo Cruz · 2025Review
- Revamping the BCG revaccination strategy: Records to recall, or just call it phoenix?Human vaccines & immunotherapeutics · 2024Article
- Enhanced Antimicrobial Peptide Response Following Bacillus Calmette-Guerin Vaccination in Elderly Individuals.Vaccines · 2024Article
- The mark of success: The role of vaccine-induced skin scar formation for BCG and smallpox vaccine-associated clinical benefits.Seminars in immunopathology · 2024Review
- Novel delivery systems for controlled release of bacterial therapeutics.Trends in biotechnology · 2024Review
- Article
- Rifampicin Resistance Pattern of Mycobacterium tuberculosis Infection in Tertiary Care Hospital Settings.Cureus · 2024Article
- Bacillus Calmette-Guérin (BCG) Revaccination and Protection Against Tuberculosis: A Systematic Review.Cureus · 2024Review
- Blood transcriptional correlates of BCG-induced protection against tuberculosis in rhesus macaques.Cell reports. Medicine · 2023Article
- Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines.Frontiers in immunology · 2023Article
- Immunomodulation resulting of helminth infection could be an opportunity for immunization against tuberculosis and mucosal pathogens.Frontiers in immunology · 2023Article
- Culture filtrate proteins from BCG act as adjuvants for cytotoxic T lymphocyte induction.Frontiers in immunology · 2023Article
- Genetic and hormonal mechanisms underlying sex-specific immune responses in tuberculosis.Trends in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The BCG vaccine will, in 2021, have been in use for 100 years. Much remains to be understood, including the reasons for its variable efficacy against pulmonary tuberculosis in adults. This review will discuss what has been learnt about the BCG vaccine in the last two decades, and whether this new information can be exploited to improve its efficacy, by enhancing its ability to induce either antigen-specific and/or non-specific effects. Many factors affect both the immunogenicity of BCG and its protective efficacy, highlighting the challenges of working with a live vaccine in man, but new insights may enable us to exploit better what BCG can do.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.